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Chemokines direct cellular infiltration to tissues, and their receptors and signaling
pathways represent targets for therapy in diseases such as multiple sclerosis (MS). The
chemokine CCL20 is expressed in choroid plexus, a site of entry of T cells to the central
nervous system (CNS). The CCL20 receptor CCR6 has been reported to be selectively
expressed by CD4+ T cells that produce the cytokine IL-17 (Th17 cells). Th17 cells and
interferon-gamma (IFNγ)-producing Th1 cells are implicated in induction of MS and its
animal model experimental autoimmune encephalomyelitis (EAE). We have assessed
whether CCR6 identifies specific inflammatory T cell subsets in EAE. Our approach was
to induce EAE, and then examine chemokine receptor expression by cytokine-producing
T cells sorted from CNS at peak disease. About 7% of CNS-infiltrating CD4+ T cells
produced IFNγ in flow cytometric cytokine assays, whereas less than 1% produced IL-17.
About 1% of CD4+ T cells produced both cytokines. CCR6 was expressed by Th1, Th1+17
and by Th17 cells, but not by CD8+ T cells. CD8+ T cells expressed CXCR3, which was
also expressed by CD4+ T cells, with no correlation to cytokine profile. Messenger RNA for
IFNγ, IL-17A, and the Th1 and Th17-associated transcription factors T-bet and RORγt was
detected in both CCR6+ and CXCR3+ CD4+ T cells. IFNγ, but not IL-17A mRNA expression
was detected in CD8+ T cells in CNS. CCR6 and CD4 were co-localized in spinal cord
infiltrates by double immunofluorescence. Consistent with flow cytometry data some but
not all CD4+ T cells expressed CCR6 within infiltrates. CD4-negative CCR6+ cells included
macrophage/microglial cells. Thus we have for the first time directly studied CD4+ and
CD8+ T cells in the CNS of mice with peak EAE, and determined IFNγ and IL17 expression
by cells expressing CCR6 and CXCR3. We show that neither CCR6 or CXCR3 align with
CD4 T cell subsets, and Th1 or mixed Th1+17 predominate in EAE.
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INTRODUCTION
Multiple sclerosis (MS) is an inflammatory demyelinating disease
of the central nervous system (CNS) whose pathogenesis involves
infiltrating immune cells, including T cells. CD4+ T cells play
a central role in orchestrating immune responses by secret-
ing cytokines that regulate various cellular functions. Effector
CD4+ T cells of Th1 and Th17 subsets are found in MS lesion
and can mediate experimental autoimmune encephalomyeli-
tis (EAE), an animal model of MS. Expression of Th1 and
Th17 cytokines, IFNγ and IL-17 is detected in MS lesions
(Steinman, 2008). EAE can be induced by the adoptive transfer
of CNS antigen reactive Th1 cells (Pettinelli and Mcfarlin,
1981; Ando et al., 1989; Merrill et al., 1992; Baron et al.,
1993) and Th17 cells (Langrish et al., 2005; Jäger et al.,
2009; Domingues et al., 2010). While EAE induced by adop-
tive transfer of Th1 cells is characterized by infiltrates pre-
dominantly comprising of macrophages, EAE induced by Th17
cells is characterized by neutrophil recruitment (Kroenke et al.,
2008).
MHC-I restricted CD8+ T cells are also suggested to play
pathogenic roles in MS and its different animal models (Huseby
et al., 2012). CD8+ T cells are present in the immune infiltrates
in MS lesions (Traugott et al., 1983). CD8+ T cells in MS lesions
are oligoclonally expanded (Babbe et al., 2000) and outnumber
CD4+ T cells as the most frequent T cell subset in MS lesions
(Hauser et al., 1986; Babbe et al., 2000). MHC-I molecules
that present antigens to CD8+ T cells are highly expressed in
astrocytes, oligodendrocytes, and neurons (axons) within the MS
lesions suggesting that CD8+ T cells can directly engage these cells
(Höftberger et al., 2004).
Migration of activated T cells into the CNS is directed by
chemokines (Holman et al., 2011) and mediated by adhesion
molecules (Engelhardt and Ransohoff, 2012). Constitutive expres-
sion of the chemokine CCL20 in choroid plexus is proposed to
act as a gateway for T cells into uninflamed CNS (Axtell and
Steinman, 2009; Reboldi et al., 2009). Th17 cells can preferentially
express CCR6, the chemokine receptor for CCL20, in vitro (Hirota
et al., 2007; Pötzl et al., 2008; Singh et al., 2008; Yamazaki et al.,
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2008; Reboldi et al., 2009). Based on the preferential expression
of CCR6 in Th17, constitutive expression of CCL20 in choroid
plexus and the requirement of CCR6 expression in CD4+ T cells
for EAE, it is proposed that CCR6 plays a critical role in the
entry of Th17 cells into the CNS in EAE and in induction of
disease (Reboldi et al., 2009). The chemokine receptor CXCR3
binds CXC chemokines such as CXCL10 and is also of interest in
EAE, although consensus is lacking on its precise role (Liu et al.,
2005; Muller et al., 2010).
Forced expression of RORγt, the transcription factor critical
for Th17 differentiation, can result in CCR6 expression (Ivanov
et al., 2006; Hirota et al., 2007). However, RORγt expression
in CD4+ T cells does not guarantee CCR6 expression in vivo.
Although CCR6 expression correlates well with RORγt expressing
IL-17 producers, CD4+ T cells that do not produce IL-17 can also
express CCR6 (Wang et al., 2009). It is not known whether Th1
cells in vivo can also express CCR6.
We have assessed whether CCR6 identifies specific inflam-
matory T cell subsets in the CNS of mice with EAE, by direct
analysis of CNS-infiltrating cells, with minimal manipulation. We
find that Th1 outnumber Th17 CD4+ T cells, and that CCR6 is
expressed by both, as well as by Th1+17. We also show that CD8+
T cells express CXCR3 rather than CCR6, and do not express IL-
17. Thus chemokine receptors do not align with cytokine profiles
amongst CNS-infiltrating T cells.
MATERIALS AND METHODS
ANIMALS
C57BL/6 (B6) female mice were purchased from Taconic (Ry,
Denmark). Mice were provided with food and water ad libitum.
The mice were allowed to acclimatize with the environment in
animal facility for a week before immunization. The experiments
were carried out in accordance with rules and regulations laid
down by Danish Justice Ministry Committee on Animal Research
(Approval Number 2012-15-2934-00110).
EAE
Mice were immunized by subcutaneous injection of 100 µl
emulsion (50 µl on each side) containing myelin oligoden-
drocyte glycoprotein (MOG) p35-55 (100 µg) and complete
Freund’s adjuvant (CFA) with heat inactivated Mycobacterium
tuberculosis H37RA (200 µg; Difco Laboratories, Detroit) in the
inguinal region. Animals received an intraperitoneal injection
(200 µl) of pertussis toxin (0.3 µg; Sigma-Aldrich, Brøndby,
Denmark) at the time of immunization and 2 days post-
immunization (dpi). MOG p35-55 was synthesized at the Cen-
ter for Experimental Bioinformatics (CEBI), Department of
Biochemistry and Molecular Biology, University of Southern
Denmark.
Mice were monitored for loss of body weight and symptoms
associated with EAE. Severity of symptoms were used to
grade EAE as follows: Grade 0, asymptomatic; Grade 1,
weak or hooked tail; Grade 2, floppy tail indicating com-
plete loss of tonus in tail; Grade 3, floppy tail and hind
limb paresis (splaying of limbs, slow or unsteady gait,
hind limbs slip off the bars while walking on the lids of
the cages), Grade 4: floppy tail and unilateral hind limb
paralysis; Grade 5, floppy tail and bilateral hind limb paral-
ysis. Animals were killed as the disease peaked, determined
by stabilization of the grade for 2 or more days, or when
they attained the ethically permitted limit of grade 5. Mice
were deeply anaesthetized and perfused intracardially with ice-
cold Phosphate Buffered Saline (PBS), and spinal cords were
dissected out.
FLOW CYTOMETRY
Spinal cords were collected in ice cold Hanks Balanced Salt
Solution (HBSS) (Invitrogen A/S, Taastrup, Denmark). Cell sus-
pensions were prepared by mechanical dissociation and forc-
ing through a 70 mm cell strainer (BD Biosciences, Brøndby,
Denmark). Myelin in the samples was removed following cen-
trifugation on 37% isotonic Percoll (GE Healthcare Bio-sciences
AB, Uppsala, Sweden).
T cells were stimulated for 9 h in 96 well plates coated with
anti-mouse CD3e (clone 145-2C11) in the presence of 1 µl/ml
GolgiPlug (BD Biosciences) that was added 2 h after plating, to
trap the cytokines within the cells.
The cells were washed and stained with PerCP/Cy5-CD8
(clone 53–6.7), FITC-CD4 (clone GK1.5) or V500-CD4 (clone
RM4-5) (BD Biosciences, Brøndby, Denmark), APC- or PE-CCR6
(clone 29-2L17) (Biolegend), PE-IL-17 (clone TC11-18H10.1)
(Biolegend), PE-Cy7-IFNγ (clone XMG1.2) (Biolegend) and
biotinylated CXCR3 (clone CXCR3-183) (Biolegend) detected
using APC- or PE-streptavidin. Individual isotype controls were
performed for each sample. Data was collected on LSRII (BD
Biosciences, San Jose, CA) and analyzed using FACS DIVA (BD
Biosciences) and FlowJo software (Tree Star, Ashland, OR).
For sorting CCR6 expressing T cells in the CNS, cells were
stained with PerCP/Cy5-CD8 (clone 53–6.7), FITC-CD4 (clone
GK1.5) and PE-CCR6 (clone 29-2L17). Cells were sorted on
a FACSVantage/Diva cell sorter (BD Biosciences) from pooled
batches of CNS isolates from 5 mice with MOG p35-55-induced
EAE. The experiment was repeated twice to generate three repli-
cate samples of T cells isolated from CNS, from separate EAE
inductions.
DOUBLE IMMUNOHISTOCHEMISTRY
Spinal cords were dissected out from PBS perfused mice, placed
in 4% paraformaldehyde (PFA, Sigma-Aldrich, Denmark) in
PBS, then immersed in 30% Sucrose and frozen as described
previously (Mony et al., 2014). Spinal cord sections (16 µm
thick) were cut on a cryostat and stored at −80◦C. In brief,
sections were postfixed in 4% PFA, and after several washes
in PBS and PBS containing 0.2% Triton-X100 (PBST), they
were then incubated with blocking solution containing 3%
Bovine serum albumin in PBST. Sections were stained with PE-
CCR6 (clone 29-2L17, Biolegend) and FITC-CD4 (clone GK1.5).
Nuclei were stained using 4′,6-diamidino-2-phenylindole (DAPI)
(Invitrogen-Molecular Probes). Isotype-matched primary anti-
bodies were used to control for non-specific staining. Images
for CCR6 expression in CD4+ T cells were acquired using an
Olympus BX51 microscope (Olympus, Denmark) connected to
an Olympus DP71 digital camera, and combined using Adobe
Photoshop CS version 8.0 to visualize double-labeled cells.
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QUANTITATIVE REAL-TIME PCR
RNA was extracted from sorted cells according to the man-
ufacturer’s protocol for TRIzol (Invitrogen Life Technologies).
Moloney murine leukemia virus RT (Invitrogen Life Tech-
nologies) was used to synthesize cDNA from the total RNA
using random hexamer primers. Quantitative Real-Time Reverse
Transcriptase- PCR assays (qRT-PCR) for IFN-γ, IL-17, T-bet,
ROR-γt, and 18S rRNA (Applied Biosystems) were performed
using ABI Prism 7300 Sequence Detection Systems (Applied
Biosystems, Foster City, CA). The following primer and probe
sequences were used: IFN-γ (Forward CATTGAAAGCCTAGA
AAGTCTGAATAAC, Reverse TGGCTCTGCAGGATTTTCATG,
Probe TCACCATCCTTTTGCCAGTTCCTCCAGMGB), IL-17
(Forward CTCCAGAAGGCCCTCAGACTAC, Reverse TGTGGT
GGTCCAGCTTTCC, Probe ACTCTCCACCGCAATGAMGB),
ROR-γt (Forward CCGCTGAGAGGGCTTCAC, Reverse TGCA
GGAGTAGGCCACATTACA, Probe AAGGGCTTCTTCCGCC
GCAGCCAGCAG TAMRA). The expression of T-bet and GM-
CSF was determined using Mm01299452-g1- and Mm00438328-
m1 TaqMan gene expression assays (Applied Biosystem),
respectively. Relative RNA levels in the samples were determined
using standard curves prepared from four-fold serial dilutions of
cDNA from a reference sample. Relative expression levels of genes
were normalized to 18S rRNA in the samples.
STATISTICAL ANALYSIS
Data was analyzed using GraphPad Prism version 6.0 (GraphPad
Software Inc., San Diego, California, USA). CCR6 expression
was analyzed using nonparametric Mann-Whitney t-test. CCR6
expression in IFNγ, IL-17 and IFNγ+IL-17+ CD4+ T cells was
analyzed by one-way ANOVA. Values of p< 0.05 were considered
statistically significant.
RESULTS
EAE was induced by immunization with MOGp35-55, a com-
monly used encephalitogen (Gold et al., 2006). Onset of disease
was usually at about day 10 and progression showed a rapid
increase in clinical score that levelled off after a few days. Our
definition of peak disease was two sequential days where clinical
score did not increase, at which point mice were sacrificed for
molecular and histological analyses. Figure 1A shows the disease
course for the animals in this study.
Infiltrating lymphocytes and leukocytes were analyzed by flow
cytometry. Gating strategies are shown in Figure 1B. Characteris-
tically for EAE, populations were quite heterogeneous, including
TCR β+ T cells and CD11b+ myeloid cells (macrophages, neu-
trophils and dendritic cells) (Zehntner et al., 2005; Gold et al.,
2006; Toft-Hansen et al., 2011). The majority (78.9 ± 2.3%,
n = 10) of T cells were CD4+. Expression of CCR6 by CD4+
and CD8+ T cells was analyzed by flow cytometry. Whereas
a large proportion (15.9 ± 7.5%, n = 23) of CD4+ T cells
expressed CCR6, almost no CD8+ T cells expressed this receptor
(Figure 1B). We have described elsewhere that the majority of
CD8+ T cells expressed CXCR3, which was variably expressed
by CD4+ T cells (Mony et al., 2014). We did not directly
assess whether individual T cells expressed both chemokine
receptors.
FIGURE 1 | EAE and flow cytometry. (A) Progression of EAE in mice
immunized with MOGp35-55 (Mean clinical scores ± SEM, n = 184).
(B) Gating strategies for flow cytometry analysis. CCR6 expression was
detected in CD4+ T cells but not CD8+ T cells in CNS. Cells in the spinal
cord were gated on the basis of size and granularity (top left), followed by
CD4 and CD8 expression (top right) and CCR6 expression (CD4+, lower left)
and (CD8+, lower right). Each sample was individually controlled for binding
of isotype-matched antibody of irrelevant specificity. (C) Gating strategy for
cell sorting. CCR6 expression was detected in both IL17 and IFNγ
producing CD4+ T cells in spinal cord. Representative gating scheme
depicting the morphological gate (top left), CD4 and CD8 gates (top middle),
and IFNγ vs IL17 expression in CD4+ T cells. Subsequently, IFNγ, IL17 and
IFNγ-IL17 dual producers were gated reative to isotype control for CCR6
expression (bottom histograms). Proportions of each subset within CNS
CD4+ isolates are shown on top of each profile, and the percentages that
expressed CCR6 are shown with the histograms.
Expression of inflammatory cytokines was measured by flow
cytometric intracellular cytokine staining. Th1 IFNγ-producing
CD4+ T cells (6.8 ± 0.7%, n = 8) greatly outnumbered other
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subsets, and together with those that produced both IFNγ and
IL-17 (Th1+17) (0.9 ± 0.2%, n = 8), cells producing IFNγ
constituted over 90% of cytokine-producing CD4+ T cells in
the CNS (Figure 1C) (also see Mony et al., 2014). Th17 IL-17-
producing CD4+ T cells constituted 0.7 ± 0.1% (n = 8) of the
total. CD8+ T cells produced IFNγ but did not produce IL-17
to any significant extent (Mony et al., 2014). Notably, CCR6 was
expressed by 30–60% of CD4+ T cells in intracellular cytokine
assays, regardless of their cytokine profiles (Figure 1C). There was
no significant bias towards or against CCR6 expression by Th1,
Th17 or Th1+17 subsets (Figures 1C, 2).
Expression of cytokines and of transcription factors that
control expression of key cytokines was also examined byQRT-
PCR analysis of cDNA from CD4+ T cell populations that were
sorted on the basis of CCR6 and CXCR3 expression from CNS
infiltrates of mice with peak EAE. Figure 3 shows that, as for
intracellular cytokines, there was no significant bias towards or
against expression of IFNγ or IL-17 message on the basis of
surface expression of either of these chemokine receptors. This
was also true for GM-CSF, a cytokine that has been implicated as
a direct encephalitogenic mediator in EAE (Kroenke et al., 2010;
Codarri et al., 2011). Similarly, no bias was seen for expression of
Tbet and RORγt, the transcription factors that control expression
of IFNγ and IL-17, respectively. Lack of detectable signal in
some of the sorted populations of CD4+ CCR6+ T cells likely
reflects low amounts of RNA in those samples. Populations sorted
on the basis of lack of expression of either CCR6 or CXCR3
showed equivalent if not greater levels of message for all cytokines
and transcription factors as those sorted for chemokine receptor
expression, although populations identified on the basis of lack of
expression of a single receptor are intrinsically less informative.
CD8+ T cells sorted from the CNS of mice with peak EAE
contained equivalent levels of mRNA for both IFNγ and GM-
CSF to those in CD4+ cells, but did not express detectable IL-17
message (Figure 3).
FIGURE 2 | CCR6 expression by IFNγ- and IL17-producing CD4+
T cells in the CNS. Cytokine producing T cells isolated from CNS of
mice with severe EAE were detected by flow cytometry following in
vitro restimulation and intracellular cytokine staining. CCR6 expression
was analyzed on cells gated for CD4 and intracellular IL-17 and IFNγ,
relative to isotype control. Bars show means ± SEM (n = 8).
We then localized CCR6-expressing cells within infiltrates by
immunofluorescence microscopy. Figure 4 shows that CCR6+
cells were numerous within infiltrates in spinal cord of mice with
peak disease, and that many of them co-expressed CD4. These
are included within the CD4+ CCR6+ cells that were sorted
and analyzed by flow cytometry. There were also a significant
number of CD4+ cells that did not express CCR6, which may
be assumed to include CXCR3+ CD4+ T cells. CCR6+ cells that
did not express CD4 were also observed (arrows). Staining with
antibody against GFAP and morphology excluded that these were
astrocytes (not shown). For technical reasons it was difficult to co-
localize CCR6 with myeloid markers in tissue sections, so we used
flow cytometry to determine whether CD11b+ cells also expressed
CCR6. Those data are shown in Figure 4B. In two separate analy-
ses we could show an increased proportion of CCR6-expressing
CD11b+CD45high (eg infiltrating, blood-derived) cells. Almost
no CD11b+ CD45dim microglia from the same isolates could be
shown to express CCR6, although we cannot exclude that a few
of these cells were CCR6+—neither of these populations were
further examined or localized. As expected, there was a signif-
icant proportion of cells expressing CCR6 within the CD45high
CD11b-negative population, which include infiltrating T cells.
Flow cytometry confirmed that CD8+ cells in CNS did not express
CCR6 (not shown).
Thus, both CD4+ T cells and macrophages expressed the
CCR6 chemokine receptor in spinal cord infiltrates of mice with
EAE.
DISCUSSION
Interplay between CNS- and immune-derived signals is central
to induction and regulation of neuroinflammatory diseases such
as MS. The possibility that chemokines might selectively recruit
T cells with distinct functional capability opens scenarios that
are both of fundamental interest as well as offering therapeutic
options. We have asked whether T cells that were recruited to the
CNS of mice with EAE show selective expression of the CCR6
chemokine receptor, that had been identified as aligning with
the IL-17-producing CD4+ Th17 cytokine subset in studies of
experimentally polarized T cells. A previous study had addressed
this by taking a post-hoc approach of measuring Th subsets that
had already infiltrated to induce severe EAE, and determining
their chemokine receptor expression, but had not examined
CCR6 or Th17 within CNS infiltrates (Fife et al., 2001). Taking
a similar approach we demonstrate, as far as we know for the first
time, that the Th1 and Th1+17 subsets, both producing IFNγ,
overwhelmingly predominated in CNS, and that many Th1 as well
as Th1+17 expressed CCR6. We also find that almost no CD8+
T cells in CNS expressed CCR6 or IL-17, but were overwhelmingly
IFNγ-producers that expressed CXCR3. Both CD4+ and CD8+
T cells expressed GM-CSF, and expression of the Th1 and Th17-
associated transcription factors T-bet and RORγt aligned with
IFNγ and IL-17 respectively.
These findings support three broad interpretative conclusions:
(1) CCR6 can be expressed by Th1 and by Th1+17 as well as
by Th17 in CNS; (2) IFNγ-producing T cells are a major com-
ponent of the neuroinflammatory response in EAE; and (3) The
spectrum of chemokines and their receptors that control immune
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FIGURE 3 | Cytokine and transcription factor (TF) gene expression by
CCR6+CD4+, CXCR3+CD4+ and CD8+ T cells in the CNS. CD4+ T cells
expressing CXCR3 or CCR6, and CD8+ T cells, were sorted from spinal
cords of mice with EAE, pooled from groups of 5 mice, in three different
experiments. IFNγ, IL-17, GM-CSF, RORγt, T-bet mRNA expression was
detected byQRT-PCR in CXCR3-expressing and CCR6-expressing, as well
as receptor-negative CD4+ T cells from the same sorts (Top 4 and bottom
left panels). Bottom right panel: CD8+ T cells in the CNS expressed IFNγ,
GM-CSF, RORγt, Tbet mRNA, but not IL-17. The y axis shows relative
levels of expression (compared to a standard curve) as a ratio to 18S
rRNA levels in the same sample. ND: not detectable (1 indicates 1 sample
only ND).
infiltration to the CNS is likely to be quite broad. These will be
discussed in turn.
CCR6 is the chemokine receptor for CCL20 (liver activa-
tion regulated chemokine, LARC or macrophage inflammatory
protein-3α, MIP3α) (Baba et al., 1997; Greaves et al., 1997;
Hieshima et al., 1997; Rossi and Zlotnik, 2000). The constitutive
expression of CCL20 in choroid plexus is proposed to act as a
gateway for T cells into uninflamed CNS (Axtell and Steinman,
2009; Reboldi et al., 2009). CCL20 and CCR6 expression are
upregulated in the spinal cord in EAE (Serafini et al., 2000).
CCL20 is expressed mainly by leukocytes infiltrating the CNS
of SJL mice at the onset (acute phase) of relapsing-remitting
EAE. CCL20 is also expressed in astrocytes after disease relapses
(chronic phase) in the SJL/J EAE model (Serafini et al., 2000;
Ambrosini et al., 2003). The cytokines IL1β, IL6, TNFα and
combinations of IL1β and TNFα, IL6 and IL-17 can induce
CCL20 in astrocyte cultures, whereas IFNγ and IL-17 do not
(Ambrosini et al., 2003; Kang et al., 2010; Meares et al., 2012).
IL1β, IL6 and TNFα expression are elevated in the brains of
mice before the onset of symptoms in EAE (Murphy et al.,
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FIGURE 4 | Cellular localization of CCR6 expression in CNS. (A)
CCR6 expression colocalized with CD4+ T cells in spinal cord infiltrates
in EAE. CCR6 expression was detected on CD4+ cells by
immunofluorescence microscopy in subpial infiltrates in EAE spinal
cord. CD4+ cells that lacked CCR6 expression can also be seen. CCR6
expression was also detected in cells that lacked CD4 expression
(arrows). Micrographs are representative of tissue from 4 mice.
Non-specific staining was evaluated by replacing CD4 and CCR6
antibodies with isotype-matched negative control antibodies. (B) Flow
cytometry analysis of CCR6 expression by CD45highCD11b+,
CD45lowCD11b+ and CD45highCD11b− cells in spinal cord of
MOGp35-55-immunized mice with EAE. Profiles show CD45 and CCR6
(bottom panels) or isotype control (top panels) staining on cells gated
by relative CD11b expression.
2010). IL-17 and downstream Act1 signaling enhanced TNF α-
induced CCL20 expression in astrocytes (Kang et al., 2010),
which could facilitate the entry of CCR6 expressing T cells into
the CNS.
The leukocytic infiltrate in EAE is heterogeneous and includes,
as well as T cells that are not specific for the disease-inducing
immunogen MOG, macrophages, neutrophils and DC. CCR6
is expressed by many cell types, including B cells, T cells,
DC, neutrophils and macrophages (Wojkowska et al., 2014 and
reviewed in Lee et al., 2013). Th17 and regulatory T cells have
come under the spotlight as CCR6+ cells that play an important
role in MS and EAE (Reboldi et al., 2009). Identification of
CD4+ T cells which do not express CCR6 in an inflamma-
tory context is therefore of interest. A defining characteristic
of chemokine immunology is redundancy, so suggestion that a
particular receptor or chemokine ligand would not be essential
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might not seem all that informative. However, the CCR6-CCL20
receptor-ligand pair is unusual in being non-redundant so neither
can be substituted by other receptors or ligands, in the context
of the paired interaction. Whether other receptor-ligand pairs
can substitute for functional outcome then becomes a question.
A recent study showed that CNS-infiltrating Th17 expressed
CXCR2 (Wojkowska et al., 2014). Whether there is an absolute
requirement for CCR6 for Th17 entry to the CNS has not been
resolved.
One potential issue for interpretation of chemokine receptor
analyses is that receptor ligation by chemokine may have led to
downregulation of the receptor. We cannot exclude that this may
have occurred and that the actual proportion of CNS-infiltrating
CCR6+ Th17 may have been higher than we estimated. However,
since relatively low but comparable (>25%, <50%) proportions
of any cytokine subset expressed CCR6, this argues against all of
these T cells depending on CCR6 for their entry to the CNS, as
well as against subset-specific dependence. Furthermore we show
no CCR6+ CD8+ T cells, although all of them had infiltrated, and
in this and another study we have shown that all of the CD8+ and
significant proportions of CD4+ (of any cytokine subset) express
CXCR3. We did not pursue the role of CXCR3+ T cells further,
and studies of the role of CXCR3+ T cells in EAE continue to
yield quite divergent findings (Liu et al., 2005; Muller et al., 2010;
Sporici and Issekutz, 2010; Lalor and Segal, 2013). Our data does
not exclude that CCR6-negative T cells had once expressed CCR6.
Despite the potential for downregulation of CCR6 expression by
T cells following encounter with CCL20, we show that Th1 as well
as mixed Th1+Th17 do express CCR6.
There is a divergent literature on the role of CCR6 in EAE.
Adoptive transfers showed that CCL20 was not required for the
effector phase of EAE, although neutralizing antibodies reduced
disease severity (Kohler et al., 2003). Mice deficient in CCR6 or
treated with blocking antibodies, although relatively resistant to
EAE, nevertheless developed mild disease (Liston et al., 2009;
Reboldi et al., 2009; Moriguchi et al., 2013). Other studies showed
that mice lacking CCR6 actually developed more severe or chronic
EAE, attributed either to reduced regulatory T cell recruitment
(Villares et al., 2009), or lack of CCR6+ PDL1+ mDC (Elhofy
et al., 2009). In all of the knockout studies, CCR6-deficient T cells
infiltrated the CNS.
The predominance of IFNγ-secreting T cells in the CNS of
mice with severe EAE is very striking. There have been conflicting
reports on the role and requirement for IFNγ in EAE. This is the
only cytokine to have been directly shown to be pro-pathogenic
in MS (Panitch et al., 1987), although that is not necessarily a
desirable or easily achievable demonstration for other cytokines.
Recent papers have provided a more nuanced perspective on the
role for IFNγ in EAE and MS, showing that timing and possi-
bly location of expression influence outcome of its expression
(Hindinger et al., 2012; Naves et al., 2013). The mixed Th1+17
subset is a prominent and consistent feature of our analyses of
MOG-induced EAE and has been implicated in MS (Kebir et al.,
2009). It has been reported that polarized Th17 can convert to
IFNγ-producing T cells in vivo (Shi et al., 2008; Bending et al.,
2009; Lee et al., 2009). One of the roles recently identified for
IFNγ is controling recruitment of Th17 (Berghmans et al., 2011),
which increases interest in the Th1+17 subset. The previously
bipolar debate on the relative roles of Th1 versus Th17 in EAE
is given broader perspective by such considerations. Also, it is
now clear that neither of the nominal cytokines for Th1 or Th17
are themselves necessary for EAE, but a third cytokine GM-CSF
plays a key role (Kroenke et al., 2010; Codarri et al., 2011). We
show that this cytokine is produced by CD4+ and CD8+ T cells
and that as for IFNγ and IL-17, there is no obvious correlation
with expression of the CCR6 or CXCR3 chemokine receptors.
Our study has not attempted to differentiate between whether
these cytokines are necessary or sufficient for disease, but does
not support that the CCR6 chemokine receptor aligns with any
of them. Expression by macrophages points to the possibility
of their interaction with CCL20-producing astrocytes, an aspect
that deserves further attention. It cannot be excluded that some
microglia may also express CCR6.
The importance of CCR6 signaling for induction of EAE is
shown by disease reduction in mice lacking this receptor, and by
studies in which the receptor or its CCL20 ligand were blocked
(Kohler et al., 2003; Liston et al., 2009; Reboldi et al., 2009). A
question that arises is whether this receptor selectively controls
entry of Th17 to the CNS. Findings from direct analysis of T cells
that had entered the CNS in established EAE do not support this,
nor do they support any association with GM-CSF producing
cells. Similarly this and another study do not support association
of CXCR3 with Th1 or IFNγ-producing T cells (Mony et al.,
2014). Importantly our analyses also identify T cells that may
not express either of these chemokine receptors. This points to
there being a wider spectrum of chemokine responses driving
EAE rather than only CCR6 and CXCR3. One candidate pathway
involves CCR2, which has three potential ligands, although it
is more implicated in regulation of macrophage entry. Other
receptors such as CCR8 have also been implicated, especially in
TNF-driven induction of glial response at the blood-brain barrier
(Mürphy et al., 2002), as well as CXCR2 (Wojkowska et al., 2014).
It has been reported that Th17 can co-express CCR4 and CCR6
(Mehling et al., 2010), but EAE (with reduced severity) could be
induced in a double knockout mouse, and CCR6-negative CD4+
T cells infiltrated the CNS (Moriguchi et al., 2013). The possibility
of substitution by other receptor-ligand interactions might help
explain lack of black-vs-white findings from ablation or blockade
of selected chemokines or their receptors.
We have used direct analyses to show lack of alignment
between chemokine receptors with T cell cytokine subsets in
the inflamed CNS. This highlights challenges for development
of chemokine-directed therapy for MS, and underlines the ele-
gance, complexity and tremendous importance of chemokines in
controling immunesurveillance as well as pathophysiologic T cell
entry to the CNS.
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